This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
ZYTIGA® (abiraterone acetate)
Medical Information
ZYTIGA - Repackaging Stability
Last Updated: 07/17/2026
- The company cannot recommend any practices, procedures, or storage conditions that deviate from product labeling. Stability is not guaranteed for ZYTIGA when stored outside of its original packaging. Defer to your institutional/local guidelines for guidance on repackaging pharmaceutical products.
- Based on its mechanism of action, ZYTIGA may harm a developing fetus. Women who are pregnant or women who may be pregnant should not handle ZYTIGA 250 mg uncoated tablets or other ZYTIGA tablets if broken, crushed, or damaged without protection, eg, gloves.1
PRODUCT LABELING
References
| 1 | ZYTIGA (abiraterone acetate) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-ecaf8e16-61b7-48c6-a6ad-2594b810a4af. |
Would you like to clear and leave your conversation? Message history will be lost.